搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

  1. 首頁(yè)
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Rat Proprotein convertase subtilisin/kexin type 9(PCSK9) ELISA kit

Rat Proprotein convertase subtilisin/kexin type 9(PCSK9) ELISA kit

  • 中文名稱(chēng)：
    大鼠前蛋白轉(zhuǎn)化酶枯草溶菌素9(PCSK9)酶聯(lián)免疫試劑盒
  • 貨號(hào)：
    CSB-EL017647RA
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    大鼠前蛋白轉(zhuǎn)化酶枯草溶菌素9(PCSK9)酶聯(lián)免疫試劑盒（CSB-EL017647RA）為競(jìng)爭(zhēng)法ELISA試劑盒，定量檢測(cè)血清、血漿、組織勻漿樣本中的PCSK9含量。PCSK9是一種重要靶點(diǎn)。其在調(diào)節(jié)肝臟表面低密度脂蛋白受體水平方面發(fā)揮關(guān)鍵作用。該靶點(diǎn)的異常會(huì)影響膽固醇代謝。相關(guān)研究聚焦于抑制PCSK9活性，以提升低密度脂蛋白受體數(shù)量，促進(jìn)膽固醇清除，為降脂治療提供新策略。試劑盒檢測(cè)范圍為93.75 pg/mL-6000 pg/mL，該產(chǎn)品可廣泛應(yīng)用于心血管疾病機(jī)制研究、代謝綜合征動(dòng)物模型分析、肝臟功能相關(guān)實(shí)驗(yàn)以及藥物開(kāi)發(fā)過(guò)程中PCSK9調(diào)控效果的評(píng)估，為科研人員探究脂質(zhì)代謝異常、動(dòng)脈粥樣硬化等領(lǐng)域的分子機(jī)制提供可靠工具。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見(jiàn)產(chǎn)品說(shuō)明書(shū)。
  • 別名：
    Pcsk9 ELISA Kit; Narc1 ELISA Kit; Proprotein convertase subtilisin/kexin type 9 ELISA Kit; EC 3.4.21.- ELISA Kit; Neural apoptosis-regulated convertase 1 ELISA Kit; NARC-1 ELISA Kit; Proprotein convertase 9 ELISA Kit; PC9 ELISA Kit; Subtilisin/kexin-like protease PC9 ELISA Kit
  • 縮寫(xiě)：
  • Uniprot No.：
  • 種屬：
    Rattus norvegicus (Rat)
  • 樣本類(lèi)型：
    serum, plasma, tissue homogenates
  • 檢測(cè)范圍：
    93.75 pg/mL-6000 pg/mL
  • 靈敏度：
    46.88 pg/mL
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測(cè)波長(zhǎng)：
    450 nm
  • 研究領(lǐng)域：
    Metabolism
  • 測(cè)定原理：
    quantitative
  • 測(cè)定方法：
    Competitive
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%      
    Three samples of known concentration were tested twenty times on one plate to assess.  
    Inter-assay Precision (Precision between assays): CV%<10%      
    Three samples of known concentration were tested in twenty assays to assess.    
                 
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of rat PCSK9 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　 Sample Serum(n=4)  
    1:100 Average % 92  
    Range % 82-98  
    1:200 Average % 93  
    Range % 87-96  
    1:400 Average % 98  
    Range % 92-104  
    1:800 Average % 87  
    Range % 82-95  
  • 回收率：
    The recovery of rat PCSK9 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range  
    Serum (n=5) 93 89-97  
    EDTA plasma (n=4) 98 96-104  
                 
                 
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/ml OD1 OD2 Average    
    6000 0.088 0.087 0.088    
    3000 0.185 0.188 0.187    
    1500 0.358 0.369 0.364    
    750 0.624 0.630 0.627    
    375 1.130 1.111 1.121    
    187.5 1.516 1.500 1.508    
    93.75 1.810 1.712 1.761    
    0 2.169 2.064 2.117    
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

引用文獻(xiàn)

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
  • 基因功能參考文獻(xiàn)：
    1. up-regulation of intestinal gene expression of LDL-R and PCSK9 following voluntary wheel running PMID: 29938676
    2. This is the first report about the expression of PCSK9 in adult terminal differentiated ventricular cardiomyocytes PMID: 28913715
    3. PCSK9 is regulated in vascular smooth muscle cells by TLR-4 - SAPK/JNK signaling, a pathway important in inflammation and metabolism. PMID: 28232185
    4. Hnf1alpha gene expression is upregulated in the liver of rats with experimentally induced chronic renal failure, showing an association between circulating PCSK9 and TAGs PMID: 26978583
    5. PCSK9 could serve as a novel molecular biomarker for the non-invasive prenatal screening of neural tube defects. PMID: 26691006
    6. coordinated up-regulation of Pcsk9 and Srebf-2 genes expression suggests that SREBF-2 may play a key role in regulation of Pcsk9 gene expression, circulating PCSK9 level, and hypercholesterolemia in experimental CRF PMID: 26481479
    7. LDLR deficiency, hypercholesterolemia and elevated plasma LDL in NS are associated with upregulation of PCSK9 and IDOL. PMID: 24166456
    8. Gene expression of hepatic LDL-R, Lrp1, Pcsk9, SREBP-2 and HMGCoA-r were reduced (p<0.05) in ovariectomy compared to Sham rats. PMID: 24619822
    9. data provided the first line of the evidence that BBR, similar to the Sim, could increase the expression of PCSK9 levels in HFD rats through SREBP-2 activation PMID: 24755036
    10. Elevated serum PCSK9 concentration by ezetimibe, Xuezhikang and pitavastatin alone or in combination was found prior to the alterations of lipid profile in rats. PMID: 24533584
    11. Phaleria macrocarpa fruit aqueous extract reduced body weight/improved blood lipid profile of hypercholesterolemic rats. The improvement is likely to be regulated by LDL receptor and PCSK9. PMID: 21763412
    12. Our functional characterization of Narc 1 reinforces the inference drawn that this enzyme is most closely related to representatives of the proteinase K family, but it is also sufficiently different to warrant its classification in a separate sub-family. PMID: 14622975
    13. Human, mouse, and rat PCSK9 promoters contain 2 typical conserved motifs for cholesterol regulation: a sterol regulatory element (SRE) and an Sp1 site. PMID: 15178557
    14. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is processed in the Endoplasmic Reticulum, and the mature convertase is secreted in the plasma. PMID: 16462892
    15. mechanism by which NARC 1 overexpression induces cell death in cerebellar granule neurons remains unclear; correlation seen between Narc 1 active site serine in transiently expressed protein and induction of BAF-sensitive component of cell death phenotype PMID: 17051583
    16. explaining the lack of reduction in LDL receptor protein levels. These observations indicate that the rate of LDL receptor cycling (function) in diabetic rats is decreased resulting in higher serum LDL levels. PMID: 18054320
    17. The hormonal and dietary regulation of hepatic LDLRs also involves posttranscriptional regulation by PCSK9. PMID: 19008317
    18. NARC-1 is a proteinase K-like subtilase with a role in the differentiation of cortical neurons. PMID: 12552133

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Cytoplasm. Secreted. Endosome. Lysosome. Cell surface. Endoplasmic reticulum. Golgi apparatus.
  • 蛋白家族：
    Peptidase S8 family
  • 組織特異性：
    Highly expressed in 12-day embryo. In the adult, strongly expressed in liver, small intestine, jejunum, and to a lesser extent in kidney, lung, spleen and thymus. Expression in the liver is up-regulated following partial hepatectomy.
  • 數(shù)據(jù)庫(kù)鏈接：